**Pneumocystis jirovecii Pneumonia in Pediatric Inflammatory Bowel Disease: A Case Report and Literature Review**

*Sally J. Lawrence*1*, Manish Sadarangani*2 and Kevan Jacobson*1

1 Department of Pediatric Gastroenterology, Hepatology and Nutrition, BC Children’s Hospital, University of British Columbia, Vancouver, BC, Canada, 2 Vaccine Evaluation Center, BC Children’s Hospital Research Institute, University of British Columbia, Vancouver, BC, Canada

Immunosuppressive therapy is a known risk factor for opportunistic infections. We report the first case of severe *Pneumocystis jirovecii* infection requiring intensive care in a pediatric patient with inflammatory bowel disease (IBD). The literature was reviewed and there were 92 reported cases of *Pneumocystis* pneumonia (PCP) in patients with IBD. Most sources were case reports and there was likely reporting bias toward patients receiving immunomodulators, anti-tumor necrosis factor (anti-TNF) therapy, and those who died. Overall, 56% of patients were males and 58% had Crohn's disease. The median age was 45 years (interquartile range 30–68, range 8–78) and 86% of patients were lymphopenic. The case-fatality rate was 23%. Corticosteroids were used as IBD treatment in 88% of patients who subsequently developed PCP, 42% received thiopurines, 44% used anti-TNF therapy, and 15% received either cyclosporine or tacrolimus. Rates of mono, dual, triple, and quadruple immunosuppression therapy were 35, 35, 29, and 2%, respectively. This report highlights the importance of considering PCP in immunosuppressed lymphopenic pediatric IBD patients who present with unusual symptoms. Moreover, it should give gastroenterologists the impetus to limit immunosuppressive therapy to its minimal effective dose and consider options such as exclusive enteral nutrition wherever possible. Although there is no place for global PCP prophylaxis in IBD given the low incidence, in an era when there is increasing use of biologic agents with combination immunosuppressive therapy, the risk-benefit profile of PCP chemoprophylaxis should be revisited in selected cohorts such as patients on triple immunosuppression with corticosteroids, thiopurines, and a biological agent or calcineurin inhibitor, especially in lymphopenic individuals.

**Keywords:** *Pneumocystis jirovecii*, pneumocystis pneumonia, inflammatory bowel disease, pediatric, opportunistic infection, immunosuppressive therapy, lymphopenia

**INTRODUCTION**

Immunosuppressive therapy is a known risk factor for opportunistic infections (1). We report a case that highlights the importance of considering opportunistic infection in immunosuppressed pediatric patients with inflammatory bowel disease (IBD) who present with unusual symptoms. We present the first case of severe *Pneumocystis jirovecii* (*P. jirovecii*) infection requiring intensive care in a pediatric patient with IBD.
CASE REPORT

A 12-year-old Caucasian girl was diagnosed with gastric and ileocolonic Crohn’s disease (CD), Paris classification L3, L4a, B1, G1, having presented with growth failure and abdominal pain and having undergone endoscopic and magnetic resonance enterography assessment. She failed exclusive enteral nutrition (EEN) and was treated with oral prednisone tapered over 3 months with maintenance azathioprine (AZA) (2 mg/kg/day). Treatment resulted in resolution of clinical symptoms and improved biochemical markers. She had recurrence of symptoms after 9 months with abdominal pain and diarrhea. Infective work-up was negative and she was commenced on oral budesonide 9 mg and her AZA dose was increased (2.5 mg/kg/day). Thiopurine metabolites at this stage were normal [6-TGN 278 pmol/8 × 10^8 (normal range 230–400), 6-MMPN 734 pmol/8 × 10^8 (normal range <5,700)].

Three months later, she presented with a 3-day history of fever, dry cough, and progressive dyspnea. On examination, she was hypoxic with SaO2 90% despite 15 l/min high flow oxygen. She had severe lymphopenia (0.0 × 10^9/l on manual count), elevated white cell count (10.8 × 10^9/l), raised C-reactive protein (268 mg/l), and lactate dehydrogenase was 763 U/l. Chest X-ray showed bilateral interstitial infiltrates (Figure 1). She required intensive care for bi-level positive airway pressure respiratory support. AZA and budesonide were discontinued and she was commenced on piperacillin–tazobactam, clarithromycin, and oseltamivir to provide empiric coverage against bacteria (including atypical) and influenza, with minimal improvement in symptoms. An induced sputum sample was negative for bacterial and viral pathogens [culture and broad panel polymerase chain reaction (PCR)] but revealed P. jirovecii on silver stain (Figure 2). Intravenous (IV) trimethoprim–sulfamethoxazole (TMP–SMX) 20 mg/kg TMP/100 mg/kg SMX and methylprednisone 1 mg/kg twice daily were initiated, which resulted in improvement in respiratory status and weaning of respiratory support over 7 days.

Prior to discharge, she was investigated for an underlying primary immunodeficiency. Human immunodeficiency (HIV) testing was negative and immunoglobulin levels were normal. B and T cell panel revealed a low absolute count of CD3, CD4, and CD8 (0.47, 0.36, 0.14 × 10^9/l respectively) with normal number of B cells (0.43 × 10^9/l), normal CD4/CD8 ratio (2.43), and a good response to previous diphtheria and tetanus vaccines. She remained lymphopenic during admission, but this slowly improved. Notably, at IBD diagnosis, she had normal lymphocyte levels [lymphocyte count 1.7–2.6 (normal range 0.9–3.5 × 10^9/l)]; however, after AZA initiation, she had intermittent lymphopenia (0.4–1.2 × 10^9/l). Thiopurine methyltransferase activity testing was unfortunately unavailable at diagnosis.

She was discharged on oral TMP–SMX for 21 days, having had 3 days of IV therapy. She received 3 days of methylprednisone followed by 5 days of oral prednisone, which was tapered over 2.5 months. AZA was restarted at a reduced dose (1.5 mg/kg/day). Within 2 months, she had normal lymphocyte numbers with a normal absolute CD4 count (0.56 × 10^9/l) and normal T-cell numbers. She developed an urticarial rash thought to be secondary to TMP–SMX 4 days post discharge and was changed to oral clindamycin and primaquine to complete the 21-day treatment course. She was then started on prophylactic oral dapsonse, which was discontinued when she developed arthralgia. She has not subsequently taken PCP prophylaxis.

One year post-PCP admission, she was commenced on adalimumab monotherapy due to ongoing poor growth, abdominal pain, and an elevated fecal calprotectin (>1,800 μg/g). This resulted in resolution of symptoms, catch-up growth, and progression through puberty. She has had no further significant infections in the last 5 years and her lymphocyte count has remained stable.

LITERATURE REVIEW AND DISCUSSION

Overview of P. jirovecii Pneumonia

Pneumocystis jirovecii (formerly known as Pneumocystis carinii) is a ubiquitous opportunistic fungus, which causes
pneumonia [Pneumocystis pneumonia (PCP)]. It was first described in 1940s malnourished infants (2). In the 1980s, it was associated with HIV-infected patients with low CD4 counts (3). PCP continues to be an acquired immunodeficiency syndrome-defining illness although the advent of antiretroviral therapy has resulted in incidence reduction (4). PCP has been recognized as a disease in children with primary cell-mediated immunodeficiency, patients receiving chemotherapy for hematological malignancies, solid organ, and bone marrow transplant recipients and in patients requiring immunosuppressants (5). Notably, the incidence in the immunosuppressed non-HIV population is increasing with the escalating use of immunosuppressive agents (4, 6, 7). Inflammatory autoimmune conditions such as IBD account for up to 20% of PCP in HIV-negative patients (8).

Pneumocystis jirovecii exposure appears to occur early in life and is often asymptomatic (9, 10). Reinfection of the immunosuppressed host through environmental or person-to-person transmission rather than reactivation from latency appears to be the major mode of acquisition in immunosuppressed patients (10). Effective host defenses against P. jirovecii are mediated by the innate, T-cell, and to a lesser extent, humoral immune responses. In immunosuppressed patients, the infection results in a dysfunctional immune response, composed of mononuclear cells, CD8 lymphocytes, and activated macrophages, which causes diffuse lung damage (11). Moreover, the inhaled Pneumocystis trophozoites inhibit epithelial repair processes within the alveoli resulting in severe lung damage (12).

Adult data show that unlike in HIV-infected individuals where presentation can be slow and insidious, non-HIV infected immunocompromised individuals can have an aggressive course often culminating in respiratory failure over several days (4, 13–15). PCP is characterized by a non-productive cough, fever, and dyspnea. On chest X-ray, diffuse bilateral interstitial pulmonary infiltrates are most common (4). In equivocal cases, high resolution chest computed tomography is more sensitive and commonly shows diffuse ground glass opacity (16).

Pneumocystis jirovecii cannot be cultured, therefore, definitive diagnosis is made by visualization of the organism’s cysts and trophozoites. This can be achieved using induced sputum, bronchoalveolar lavage specimens, or lung tissue stained with Grocott–Gomori’s methenamine silver or visualized using immunofluorescence. Unfortunately, sensitivity is <67% in the non-HIV infected patient due to low numbers of P. jirovecii (17). PCR testing of P. jirovecii nucleic acid in respiratory samples is more sensitive for diagnosis; however, discrimination between colonization and actual disease has been challenging. Quantitative PCR is thought to help differentiate between these two entities better than qualitative PCR with recent research focusing on oral washes as a less invasive diagnostic tool (18, 19).

First line treatment of PCP is IV TMP–SMX (15–20 mg/kg/24 h of the trimethoprim component in three divided doses) due to excellent tissue penetration, rapid response, and low cost (4). Adverse reactions include leukopenia, thrombocytopenia, and rashes including Stevens–Johnson syndrome (5). However, reactions appear less common in children (20). Alternative therapy includes clindamycin plus primaquine, pentamidine, and dapsone (21). Atovaquone has been used for mild disease as it is less effective than TMP–SMX, but better tolerated (22). Corticosteroids have been used as an adjuvant treatment in severe disease, reducing respiratory failure and the length of intensive care unit stay (23).

PCP mortality rates are between 20 and 60% in immunocompromised non-HIV infected individuals in contrast to rates of 10–20% in HIV-infected patients (4, 7, 13, 15, 24, 25). The more severe course is thought to be secondary to a more disseminated pulmonary inflammatory response and diagnostic delay (4, 26).

PCP and IBD

A retrospective cohort study determined that IBD patients were at an elevated risk of PCP compared to the general population with an increased relative risk (hazard ratio 2.96; 95% CI 1.75–4.29) but low absolute risk (0.03%) (26). The incidence of PCP in immunosuppressed IBD patients [thiopurines, methotrexate, calcineurin inhibitors, anti-tumor necrosis factor (anti-TNF) agents, or steroids] was 32/100,000 patient-years (PY) compared to 5.5/100,000 PY for non-immunosuppressed IBD patients (26). The risk appeared greater in CD compared with ulcerative colitis (UC) (26). In another population-based IBD cohort, double immunosuppression resulted in a higher risk of PCP than monotherapy (0.6/100 vs. 0.3/100 PY). There were few patients on triple therapy making risk analysis challenging (27).

There is only one published case of a child with IBD developing PCP. The 8-year-old CD patient, on infliximab monotherapy, developed PCP with concurrent disseminated histoplasmosis after 15 months therapy. His disease course was not severe. He did not require respiratory support and responded to TMP–SMX. He was maintained on budesonide with no PCP prophylaxis (28). PCP has been described in adult IBD patients on corticosteroids, calcineurin inhibitors, thiopurines, and anti-TNF agents (8, 26, 29–33).

We performed a literature review of PCP in IBD. A database search for studies on MEDLINE, EMBASE, and the Cochrane Controlled Trials Registry was performed. References of included articles were searched for further studies. Table 1 summarizes the details of published IBD studies reporting patients with PCP. Most sources were case reports [evidence level 5 (34)], and there was likely reporting bias toward immunomodulators, anti-TNF therapy, and patients who died. There were 92 reported cases of PCP in patients with IBD in the English literature, of which 56% were males and 58% had CD. The median age was 45 years [interquartile range (IQR) 30–68, range 8–78]. There was little documented information about CD4 counts at PCP diagnosis; however, 86% (12/14) of patients were lymphopenic. The case-fatality rate (CFR) was 23% (7/31) based on the reported outcome data. Where medication was documented, rates of mono, dual, triple, and quadruple immunosuppression therapy were 35% (18/52), 35% (18/52), 29% (15/52), and 2% (1/52), respectively. The numbers were too small to comment on the effect of incremental risk with increasing numbers of immunosuppressants. Corticosteroids, as mono, dual or triple therapy, were used as IBD treatment, in 88% (46/52) of patients who developed PCP. 42% (22/52)
TABLE 1 | Summary of published literature of inflammatory bowel disease patients who developed pneumocystis pneumonia (n = 92).

| Reference | No of patients | Disease subtype | Gender | Age (years) | Medication at time of PJP | Single (S), dual (D), triple (TR), quadruple (Q) immunosuppression | Outcome |
|-----------|----------------|-----------------|--------|-------------|--------------------------|---------------------------------------------------------------|---------|
| Khatchatourian and Seaton (30) | 1 | UC | M | 68 | CS + T | D | Died |
| Lee et al. (35) | 1 | UC | M | 21 | CS + T | D | Survived |
| Takenaka et al. (36) | 3 | UC (100%) | F (87%) | 26–68 | CS + T (67%), CS (33%) | D (67%) | Survived (100%) |
| Bernstein et al. (29) | 2 | UC (100%) | M (100%) | 32–73 | CS + Tac, CS (67%), CS (33%) | TR (50%) | Died (50%) |
| Takenaka et al. (36) | 3 | UC (100%) | F (67%) | 26–68 | CS + Tac, CS (67%), CS (33%) | TR (50%) | Survived (100%) |
| Lee et al. (35) | 1 | UC | M | 21 | CS + T | D | Survived |

CS, corticosteroids; T, thiopurines (azathioprine/6-Mercaptopurine); Tac, tacrolimus; CSA, cyclosporine; anti-TNF, anti-tumor necrosis factor therapy (adalimumab or infliximab); MTX, methotrexate; MMF, mycophenolate mofetil; IMs, immunomodulators (thiopurine, tacrolimus); ND, not documented; CD, Crohn’s disease; UC, ulcerative colitis; IQR, interquartile range.

PCP and Corticosteroids
Corticosteroids are known to reduce CD4 lymphocytes, which predisposes as a major contributor to PCP development (51). Corticosteroids have emerged as a major contributor to PCP in the non-HIV immunosuppressed population and the risk is particularly increased at or above 16 mg of prednisolone (50–52). The median therapy duration prior to PCP was 8–12 weeks (50, 51). Interestingly, in some studies, the disease only became apparent when corticosteroids were tapered (24, 50, 51).

PCP and Thiopurines
Thiopurines (AZA and 6-mercaptopurine) can inhibit cell-mediated immunity, which influences PCP development. In the literature, two IBD patients on thiopurine monotherapy developed PCP, 10 were on dual therapy, as was the case with our patient, and 10 were on triple therapy. The CFR in this group was 19% (3/16), where outcome data were available.

PCP and Calcineurin Inhibitors
Cyclosporine works by inhibiting production of IL-2 by helper T-cells and by affecting T-cell, B-cell, neutrophil, and mast cell function. In the literature, 50% (4/8) of IBD patients with PCP died (32, 37, 38). Such cases have prompted a discussion regarding the role of prophylactic antibiotics in patients on cyclosporine; however, the limited cases and reporting bias needs to be considered (37, 53, 54).

PCP and Methotrexate
Three patients in the IBD literature developed PCP while on methotrexate in combination with corticosteroid and anti-TNF therapy. Methotrexate has been implicated in the development of PCP in rheumatoid arthritis with 28 documented cases, 25% of whom died (55, 56).
PCP and Anti-TNF Agents

Cytokines inhibited by anti-TNF agents are involved in the host response to PCP resulting in reduced PCP clearance. Moreover, anti-TNF therapy can lower CD4 counts making patients more susceptible to PCP (57). Review of the Food and Drug Administration Adverse Event Reporting System data between 1998 and 2003 identified 84 patients with PCP associated with infliximab, with a mean age of 55 years; 19% of patients had IBD. Concomitant immunosuppressive agents included immunomodulators (66%), corticosteroids (50%), and cyclosporine (5%). The CFR was 27% (33). PCP has been reported to occur 9–14 weeks after the first infliximab induction dose (33, 57, 58). Notably, Colombel et al. did not report any cases of PCP associated with 3,160 patients (in six global clinical trials) on adalimumab (59). However, there are two case reports of PCP in IBD patients on adalimumab (8, 40). In total, 162 cases of PCP are reported in the IBD and rheumatology literature associated with anti-TNF therapy, which includes pediatric patients. Of the 138 patients with outcome information available, 20% died. Unfortunately, studies do not always specify whether single, double, or triple immunosuppression was used (8, 26–28, 33, 40–49, 56, 58, 60, 61). Data on the incidence of PCP in patients on anti-TNF agents are largely based on rheumatoid arthritis studies and most are population based. The majority of studies report incidence rates <50 cases per 100,000 PY (62). Results are hampered by heterogeneity in the method of PCP diagnosis, moreover, discrimination between P. jirovecii colonization and actual disease can be challenging.

There are no published data on PCP associated with vedolizumab, ustekinumab, or other novel IBD treatments (63, 64). More long-term data are required to assess safety profiles of these agents.

Other Risk Factors for PCP in Non-HIV Infected Immunosuppressed Patients

The use of multiple immunosuppressive agents incrementally increases the risk of opportunistic infection in IBD; moreover, malnutrition and surgery can play a role, although this has not been specifically addressed in PCP (1, 27, 40, 51, 52, 62). As documented in our case, lymphopenia (especially CD4 count <300 cells/mm³) has been associated with increased risk of PCP in 60–95% of cases (5, 24, 50, 65). Notably, not all immunosuppressed patients will present with lymphopenia (24, 65).

Long et al. reviewed a case series of 38 IBD patients who developed PCP and showed that rates of hospitalization at some stage within 60 days of PCP were high (50%) (26). Moreover, patients had higher rates of comorbidities, principally, lung disease and diabetes mellitus, compared to the background population. Advanced age >65 years was found to be an additional risk (26).

PCP in Other Pediatric Non-HIV Immunosuppressive Conditions

A population-based cohort study in juvenile idiopathic arthritis patients reported an incidence of 7/100,000 PY (66). Multiple immunosuppressive agents and lymphopenia are important risk factors in rheumatic diseases (67). The risk of PCP in pediatric cancer depends on the malignancy type and chemotherapy category. Lymphoid malignancies have the highest risk with rates of 22–45% (68). The overall risk of PCP post solid organ transplant has been estimated to be 5–15% in the absence of PCP prophylaxis (5). Risk factors include malnutrition, previous cytomegalovirus infection, and underlying lung disease. Medications such as steroids, antilymphocyte agents, calcineurin inhibitors, and biological agents such as alemtuzumab (anti-CD52 monoclonal antibody) have also been implicated (5).

Prophylaxis against PCP

In a 2012 survey of PCP prophylaxis practice by gastroenterologists, 11% prescribed prophylaxis to their patients with IBD on combination therapy. Gastroenterologists were more likely to prescribe if they had previous practical experience of PCP, or practiced in an academic center (69).

The effects of PCP can be severe, however, prevention entails using drugs with adverse effects that may counterbalance the benefits, as occurred in our patient. The guidelines for PCP prophylaxis in HIV-infected patients have been universally adopted, but there is a lack of consensus on prophylaxis with TMP–SMX in IBD patients. A recent Cochrane meta-analysis of prophylactic treatment with TMP–SMX in non-HIV infected patients included 1,412 patients, of which 520 were children. The authors were unable to find published literature addressing prophylaxis in IBD. In patients with hematological cancers and transplant recipients, they reported an 85% reduction in PCP incidence with prophylaxis and PCP-related mortality reduced by 83% with few adverse events reported (20). No children in the included studies had a severe adverse event compared to 3.1% of adults suggesting a lower probability of harm in children.

There is insufficient evidence to recommend PCP prophylaxis for all IBD patients on immunosuppressive monotherapy; however, with increasing number of immunosuppressive agents, the risk of opportunistic infection is known to increase (1, 27, 62). Large studies assessing the specific incremental increased risk associated with multiple immunosuppressive agents especially triple therapy have not been done. This needs to be considered, as the use of multiple immunosuppressive agents is increasing. A recent study showed that approximately half of patients started on anti-TNF therapy were already on two immunosuppressive agents (40). Dietary therapies (EEN, partial enteral nutrition, and exclusion diets) in CD are increasingly being used and investigated and are attractive options to limit immunosuppression and improve nutrition in this population (70–72).

A study using simulation modeling to address cost and comparative effectiveness of PCP prophylaxis in CD concluded that at the present incidence, routine chemoprophylaxis was not cost effective but, based on limited data, it may be effective in triple immunosuppressive therapy (73). The 2014 European Crohn’s and Colitis opportunistic infection guidelines recommend PCP prophylaxis in IBD patients on triple immunosuppression including either a calcineurin inhibitor or anti-TNF therapy. This recommendation is based on expert gastroenterology and infectious disease opinion (74). Other practical approaches proposed for patients on high-dose steroids and multiple immunosuppressants include measurement
of CD4 counts in those patients with a total lymphocyte count of <600 cells/mm³ as a means of identifying patients at risk of infections, although not all patients who develop PCP have lymphopenia, therefore, precluding its use as an isolated risk identification guide (24, 43, 65, 75). Evaluating the utility of measuring CD4 counts in IBD patients on multiple immunosuppressants should be considered.

**CONCLUSION**

We described a case of severe PCP in an immunosuppressed lymphopenic pediatric IBD patient. This case reiterates the importance of limiting immunosuppression to its minimal effective dose. Although the incidence of PCP in the IBD population is low, it is an aggressive condition that has a higher relative risk in IBD patients compared to the general population. Moreover, it is associated with significant morbidity and mortality. PCP should be considered in the differential diagnosis of immunosuppressed pediatric IBD patients who develop respiratory symptoms, with a low threshold for treatment. Although there is no place for global PCP prophylaxis in IBD, in an era where there is increasing use of biologic agents with combination immunosuppressive therapy, the risk-benefit profile of PCP prophylaxis should be revisited in selected cohorts such as patients on triple immunosuppression with corticosteroids, thiopurines, and a biological agent or calcineurin inhibitor especially in lymphopenic individuals. Further studies are required to guide definitive PCP prophylaxis in high risk subgroups of IBD patients.

**INFORMED CONSENT**

Written informed consent for publication of the case report and figures was obtained from the patient and parents.

**AUTHOR CONTRIBUTIONS**

SL performed the literature review and wrote the manuscript. MS and KJ critically reviewed the manuscript.

**ACKNOWLEDGMENTS**

The authors thank Dr. Oana Popescu for pathology slide images and Dr. Orlee Gutman for providing case information.

**REFERENCES**

1. Toruner M, Lofts EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. *Gastroenterology* (2008) 134(4):929–36. doi:10.1053/j.gastro.2008.01.012

2. Venek J, Jirovec O. [Parasitic pneumonia. Intestinal plasma cell pneumonia of premature, caused by *Pneumocystis carinii*]. *Zentralbl Bakteriol Parasitenkd Infektsr Hyg* (1952) 158(1–2):120–7.

3. Masur H, Michels MA, Greene JB, Onorato I, Stouwe RA, Holzman RS, et al. Colonization by *Pneumocystis jirovecii* and its role in disease. *Clin Microbiol Rev* (2012) 25(2):297–317. doi:10.1128/CMR.00013-12

4. Gigliotti F, Wright TW. *Pneumocystis jirovecii* pneumonia among groups at risk in HIV-negative patients. *Am J Med* (2014) 127(12):1242.e11–7. doi:10.1016/j.amjmed.2014.07.010

5. Fillatre P, Decaux O, Jouneau S, Revest M, Gacouin A, Robert-Gangneux F, et al. Incidence of *Pneumocystis jiroveci* pneumonia among groups at risk in HIV-negative patients. *Am J Med* (2014) 127(12):1242.e11–7. doi:10.1016/j.amjmed.2014.07.010

6. Limper AH, Martin WJ II. *Pneumocystis carinii* pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. *Ann Intern Med* (1984) 100(5):663–71. doi:10.7326/0003-4819-100-5-663

7. Monnet X, Vidal-Petiot E, Osman D, Hamzaoui O, Durrbach A, Joucard C, et al. Critical care management and outcome of severe *Pneumocystis pneumonia* in patients with and without HIV infection. *Crit Care* (2008) 12(1):R28. doi:10.1186/cc6806

8. Kovacs JA, Hiemenz JW, Maher AM, Stover D, Murray HW, Shelhamer J, et al. *Pneumocystis carinii* pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. *Ann Intern Med* (1984) 100(5):663–71. doi:10.7326/0003-4819-100-5-663

9. Fillatre P, Decaux O, Jouneau S, Revest M, Gacouin A, Robert-Gangneux F, et al. Incidence of *Pneumocystis jiroveci* pneumonia among groups at risk in HIV-negative patients. *Am J Med* (2014) 127(12):1242.e11–7. doi:10.1016/j.amjmed.2014.07.010

10. Limper AH, Offord KP, Smith TF, Martin WJ II. *Pneumocystis jiroveci* pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. *Am Rev Respir Dis* (1989) 140(5):1204–9. doi:10.1164/ajrccm/140.5.1204

11. Vidal CJ, Lund M, Sorensen A, Ellermann-Eriksen S, Jespersen B, Dam MY, et al. Detection of *Pneumocystis jiroveci* in oral wash from immunosuppressed patients as a diagnostic tool. *PloS One* (2017) 12(3):e0174012. doi:10.1371/journal.pone.0174012

12. Hviid C, Lund M, Sorensen A, Ellermann-Eriksen S, Jespersen B, Dam MY, et al. *Pneumocystis jiroveci* pneumonia among groups at risk in HIV-negative patients. *Am J Med* (2014) 127(12):1242.e11–7. doi:10.1016/j.amjmed.2014.07.010

13. Monnet X, Vidal-Petiot E, Osman D, Hamzaoui O, Durrbach A, Joucard C, et al. Critical care management and outcome of severe *Pneumocystis pneumonia* in patients with and without HIV infection. *Crit Care* (2008) 12(1):R28. doi:10.1186/cc6806

14. Fillatre P, Decaux O, Jouneau S, Revest M, Gacouin A, Robert-Gangneux F, et al. Incidence of *Pneumocystis jiroveci* pneumonia among groups at risk in HIV-negative patients. *Am J Med* (2014) 127(12):1242.e11–7. doi:10.1016/j.amjmed.2014.07.010

15. Monnet X, Vidal-Petiot E, Osman D, Hamzaoui O, Durrbach A, Joucard C, et al. Critical care management and outcome of severe *Pneumocystis pneumonia* in patients with and without HIV infection. *Crit Care* (2008) 12(1):R28. doi:10.1186/cc6806

16. Gruden JF, Huang L, Turner J, Webb WR, Merrifield C. High-resolution CT in the evaluation of clinically suspected *Pneumocystis carinii* pneumonia in AIDS patients with normal, equivocal or non specific radiographic findings. *Am J Roentgenol* (1997) 169:967–75. doi:10.2214/ajr.169.4.9308446

17. Limper AH, Offord KP, Smith TF, Martin WJ II. *Pneumocystis jiroveci* pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. *Am Rev Respir Dis* (1989) 140(5):1204–9. doi:10.1164/ajrccm/140.5.1204

18. Hviid C, Lund M, Sorensen A, Ellermann-Eriksen S, Jespersen B, Dam MY, et al. Detection of *Pneumocystis jiroveci* in oral wash from immunosuppressed patients as a diagnostic tool. *PloS One* (2017) 12(3):e0174012. doi:10.1371/journal.pone.0174012

19. Flori R, Bellec B, Durand F, Rabiner H, Cazorla C, Hafid J, et al. Comparison between real-time PCR, conventional PCR and different staining techniques for diagnosing *Pneumocystis jiroveci* pneumonia from bronchoalveolar lavage specimens. *J Med Microbiol* (2004) 53(Pt 7):603–7. doi:10.1099/jmm.0.45528-0

20. Stern A, Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for *Pneumocystis pneumonia* (PCP) in non-HIV immunocompromised patients. *Cochrane Database Syst Rev* (2014) 10:CD005590. doi:10.1002/14651858.CD005590.pub3

21. Smego R, Nagar S, Maloba B, Popara M. A meta-analysis of salvage therapy for *Pneumocystis carinii* pneumonia. *Arch Intern Med* (2001) 161:1529–33. doi:10.1001/archinte.161.12.1529

22. Hughes W, Leong G, Kramer F. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat *Pneumocystis carinii* pneumonia.
pneumonia in patients with AIDS. *N Engl J Med* (1993) 328:1521–7. doi:10.1056/NEJM199305273281504

23. Parekh GC, Cohen J, Razi K, Liozel H. Use of adjunctive corticosteroids in severe adult non-HIV *Pneumocystis carinii* pneumonia. *Chest* (1998) 113(5):1215–24. doi:10.1378/chest.113.5.1215

24. Overgaard UM, Helweg-Larsen J. *Pneumocystis jiroveci* pneumonia (PCP) in HIV-1-negative patients: a retrospective study 2002–2004. *Scand J Infect Dis* (2007) 39(6–7):589–95. doi:10.1080/03696980701413540

25. Mansharamani NG, Garland R, Delaney D, Koziel H. Management and outcome patterns for adult *Pneumocystis carinii* pneumonia, 1985 to 1995. *Chest* (2000) 118(3):704–11. doi:10.1378/chest.118.3.704

26. Long MD, Farraye FA, Okafor PN, Martin C, Sandler RS, Kappelman MD. Increased risk of *pneumocystis jiroveci* pneumonia among patients with inflammatory bowel disease. *Inflamm Bowel Dis* (2013) 19(5):1018–24. doi:10.1097/MIB.0b013e3182802e8b

27. Cotter TG, Gathaiya N, Catania J, Loftus EV Jr, Tremaine WJ, Baddour LM, et al. *Pneumocystis carinii* pneumonia in patients with ulcerative colitis treated with corticosteroids. *Pneumocystis carinii* *Nutr J Pediatr Gastroenterol Hepatol* (1994) 16(3):233–7. doi:10.1111/j.1558-0758.1994.tb00058.x

28. Tschudy J, Michal S. Disseminated histoplasmosis and *Pneumocystis carinii* in a child with Crohn disease receiving infliximab. *J Pediatr Gastroenterol Nutr* (2010) 51(2):221–2. doi:10.1097/MPG.0b013e3181c2c10d

29. Bernstein CN, Kolodny M, Block E, Shanahan F. *Pneumocystis carinii* pneumonia in patients with ulcerative colitis treated with corticosteroids. *Am J Gastroenterol* (1993) 88(4):574–7.

30. Khachatourian M, Seaton TL. An unusual complication of immunosuppressive therapy in inflammatory bowel disease. *Am J Gastroenterol* (1997) 92(9):1558–60.

31. Scott AM, Myers GA, Harms BA. *Pneumocystis carinii* pneumonia postoperative proctocolectomy for ulcerative colitis: a role for perioperative prophylaxis in the cyclosporine era? Report of a case and review of the literature. *Dis Colon Rectum* (1997) 40(8):973–6. doi:10.1016/S0012-4600(97)00035-0

32. Escher M, Stange EF, Herrlinger KR. Two cases of fatal *pneumocystis jiroveci* pneumonia as a complication of tacrolimus therapy in ulcerative colitis – a need for prophylaxis. *J Crohns Colitis* (2010) 4(5):606–9. doi:10.1016/j.jcjo.2010.05.004

33. Kaur N, Mahl TC. *Pneumocystis jiroveci* pneumonia after infliximab therapy: a review of 84 cases. *Dig Dis Sci* (2007) 52(6):1481–4. doi:10.1007/s10620-006-9250-x

34. Howick J, Chalmers I, Glasziou P, Heneghan C, Liberati A, Moher D, et al. General principles of medical therapy of inflammatory bowel disease: the costs of immunosuppression. *BMJ* (2000) 320:618–20. Erratum in: *BMJ* (2001) s100004.32735.c2

35. Friedmann S. General principles of medical therapy of inflammatory bowel disease. *Gastroenterol Clin North Am* (2004) 33(2):191–208. doi:10.1016/j.gtc.2004.02.003

36. Stenger AAME, Houtman PM, Bruyn GAW, Eggink HF, Pasma HR. *Pneumocystis carinii* pneumonia in patients with ulcerative colitis and inflammation in the cyclosporine era? Report of a case and review of the literature. *Dis Colon Rectum* (1997) 40(8):973–6. doi:10.1016/S0012-4600(97)00035-0

37. Kaur N, Mahl TC. *Pneumocystis jiroveci" pneumonia after infliximab therapy: a review of 84 cases. *Dig Dis Sci* (2007) 52(6):1481–4. doi:10.1007/s10620-006-9250-x

38. Lawrance IC, Radford-Smith GL, Bampton PA, Andrews JM, Tan PK, Robinson AM, Lau W, Li J, et al. Serious infections in patients with inflammatory bowel disease: when should prophylaxis be considered? *Inflamm Bowel Dis* (2013) 19(8):1764–71. doi:10.1002/ibd.20912257

39. Roberts MR, Codet C, Moal G, Baro F, Fouad M, Sibaud M, et al. Analysis of underlying diseases and prognosis factors associated with *Pneumocystis carinii* pneumonia in immunocompromised HIV-negative patients. *Eur J Clin Microbiol Infect Dis* (2002) 21(7):523–31. doi:10.1007/s10096-002-0758-5

40. Yue SH, Limper AH. *Pneumocystis carinii* pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. *Mayo Clin Proc* (1996) 71(1):13–13. doi:10.4065/71.1.5

41. Okafor PN, Nunes DP, Farraye FA. *Pneumocystis jiroveci" pneumonia in patients with inflammatory bowel disease: when should prophylaxis be considered? Inflamm Bowel Dis* (2013) 19(8):1764–71. doi:10.1002/ibd.20912257

42. Poppers DM, Scherl EL. Prophylaxis against *Pneumocystis jiroveci" pneumonia in patients with inflammatory bowel disease: toward a standard of care. *Inflamm Bowel Dis* (2008) 14(1):106–13. doi:10.1002/ibd.20261

43. Friedman S. General principles of medical therapy of inflammatory bowel disease. *Gastroenterol Clin North Am* (2004) 33(2):191–208. doi:10.1016/j.gtc.2004.02.003

44. Stenger AAME, Houtman PM, Bruyn GAW, Eggink HF, Pasma HR. *Pneumocystis carinii" pneumonia associated with low dose methotrexate treatment for rheumatoid arthritis. *Scand J Rheumatol* (2009) 38(1):51–3. doi:10.1080/03009749.2008.1021377

45. Watanabe K, Sakai R, Koike R, Sakai F, Sugiyama H, Tanaka M, et al. Clinical characteristics and risk factors for *Pneumocystis jiroveci" pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case-control study of 17 patients. *Mod Rheumatol* (2013) 23(6):1085–93. doi:10.1165/1012-0796-5

46. DelFilippis EM, Shaikh F, DeMauro A, Scherl EL, Bosworth BP. *Pneumocystis jiroveci" pneumonia in patients with inflammatory bowel disease: the costs of immunosuppression. *J Gastrointest Dig Syst* (2015) 5(1):133–4. doi:10.4172/2161-609X.1000352

47. Komano Y, Harigai M, Koike R, Sugiyama H, Ogawa J, Saito K, et al. *Pneumocystis carinii" pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. *Arthritis Rheum* (2009) 61(3):305–12. doi:10.1002/art.24283

48. Colombel JF, Sandborn WJ, Panaccione R, Robinson AM, Lau W, Li J, et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. *Inflamm Bowel Dis* (2009) 15(9):1308–19. doi:10.1002/ibd.20956

49. Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. *Ann Rheum Dis* (2008) 67(2):189–94. doi:10.1136/annrheumdis.2007.072987

50. Tai T. *Pneumocystis carinii" pneumonia after infliximab treatment: implications for chemoprophylaxis. *Curr Rheumatol Rep* (2014) 16(10):445. doi:10.1007/s11926-014-0445-4
63. Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D’Haens G, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. *Gut* (2017) 66(3):399–41. doi:10.1136/gutjnl-2015-311079

64. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. *N Engl J Med* (2016) 375(20):1946–60. doi:10.1056/NEJMoa1602773

65. Mansharamani NG, Balachandran D, Vernovsky I, Garland R, Koziel H. Peripheral blood CD4+ T-lymphocyte counts during *Pneumocystis carinii* pneumonia in immunocompromised patients without HIV infection. *Chest* (2000) 118(3):712–20. doi:10.1378/chest.118.3.712

66. Beukelman T, Xie F, Baddley JW, Chen L, Delzell E, Grijalva CG, et al. Brief report: incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. *Arthritis Rheum* (2013) 65(5):1384–9. doi:10.1002/art.37866

67. Godeau B, Coutant-Perronne V, Le Thi Huong D, Guillemin L, Magadur G, De Bandt M, et al. *Pneumocystis carinii* pneumonia in the course of connective tissue disease: report of 34 cases. *J Rheumatol* (1994) 21(2):246–51.

68. Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. *Clin Infect Dis* (2002) 34:1098–107. doi:10.1086/339548

69. Okafor PN, Wasan SK, Farraye FA. *Pneumocystis jiroveci* pneumonia in patients with inflammatory bowel disease: a survey of prophylaxis patterns among gastroenterology providers. *Inflamm Bowel Dis* (2013) 19(4):812–7. doi:10.1097/MIB.0b013e3182802964

70. Albag zamahmad MH, Day AS, Lemberg DA, Leach ST. An update of the role of nutritional therapy in the management of Crohn’s disease. *J Gastroenterol* (2012) 47(8):87–82. doi:10.1007/s00535-012-0617-9

71. Sigall-Boneh R, Pfeffer-Gik T, Segal I, Zangen T, Boaz M, Levine A. Partial enteral nutrition with a Crohn’s disease exclusion diet is effective for induction of remission in children and young adults with Crohn’s disease. *Inflamm Bowel Dis* (2014) 20(8):1353–60. doi:10.1097/MIB.0000000000000110

72. Riemmele FM, Veres G, Kolho KL, Griffiths A, Levine A, Escher JC, et al. Consensus guidelines of ECOO/ESPGHAN on the medical management of pediatric Crohn’s disease. *J Crohns Colitis* (2014) 8(10):1179–207. doi:10.1016/j.crohns.2014.04.005

73. Okafor PN, Farraye FA, Okafor AT, Erim DO. Cost-effectiveness of prophylaxis against *Pneumocystis jiroveci* pneumonia in patients with Crohn’s disease. *Dig Dis Sci* (2015) 60(12):3743–55. doi:10.1007/s10620-015-3796-4

74. Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. *J Crohns Colitis* (2014) 8(6):443–68. doi:10.1016/j.crohns.2013.12.013

75. Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel JF. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. *Gut* (2008) 57(4):549–58. doi:10.1136/gut.2006.114660

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Lawrence, Sadarangani and Jacobson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.